Atrial fibrillation is the most common cardiac arrhythmia. It is responsible for up to 20% of all ischemic strokes. Rate control and anticoagulation are crucial for atrial fibrillation management and stroke prevention.
We present the case of an 84-year-old Italian woman with a left atrial appendage thrombus that developed despite her use of anticoagulant therapy with warfarin for a previous pulmonary embolism. She had atrial fibrillation and heterozygosity for both factor V Leiden and methylenetetrahydrofolate reductase C677T mutation, thus creating resistance to activated protein C. Anticoagulant therapy was switched to heparin for 1 week and then to rivaroxaban. After 3 months of rivaroxaban use, the thrombus disappeared.
This case raises the issue of the ineffectiveness of warfarin therapy in complex cases involving particular thrombophilic conditions and the possibility of using rivaroxaban as a safe and effective alternative.
Haastrup P, Rudbæk T, Bove J. Resistance to warfarin in a patient with hereditary thrombophilia. Ugeskr Laeger. 2013;175:2572–3. PubMed
Dattilo G, Falanga G, Casale M, D’Angelo M, Quattrocchi S, Lamari A, et al. Oral anticoagulants: old and new therapy. In: Berhardt LV, editor. Advances in Medicine and Biology, vol. 83. New York: Nova Science Publishers; 2015. p. 13–71.
Ogawa S, Ikeda T, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, et al. Rivaroxaban PostMarketing Surveillance Registry Investigators. Present profiles of novel anticoagulant use in Japanese patients with atrial fibrillation: insights from the Rivaroxaban Postmarketing Surveillance Registry. J Stroke Cerebrovasc Dis. 2014;23:2520–6. CrossRefPubMed
Piccini JP, Sievert H, Patel MR. Left atrial appendage occlusion: rationale, evidence, devices, and patient selection. Eur Heart J. 2016. doi: 10.1093/eurheartj/ehw330.
European Medicines Agency. Xarelto summary of product characteristics. 2014. European Medicine Agency http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Accessed 15 Sept 2014.
Lip GYH, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B, et al. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2016;178:126–34. CrossRefPubMed
- Rivaroxaban as an effective alternative to warfarin in a patient with atrial fibrillation, thrombophilia, and left atrial appendage thrombus: a case report
- BioMed Central